alpha-Neu5Ac-(2->8)-alpha-Neu5Ac-(2->3)-beta-Gal-(1->3)-beta-GalNAc-(1->4)-beta-Gal-(1->4)-beta-Glc-(1<->1')-Cer

Term ID

CHEBI:87990

Synonyms

(2S,3R,4E)-2-(acylamino)-3-hydroxyoctadec-4-en-1-yl 5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranonosyl-(2->8)-5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranonosyl-(2->3)-beta-D-galactopyranosyl-(1->3)-2-acetamido-2-de
(Gal)2 (GalNAc)1 (Glc)1 (Neu5Ac)2 (Cer)1
alpha-Neu5Ac-(2->8)-alpha-Neu5Ac-(2->3)-beta-Galp-(1->3)-beta-GalpNAc-(1->4)-beta-Galp-(1->4)-beta-Glcp-(1<->1')-Cer
ganglioside GD1c
GD1c
NeuAcalpha2-8NeuAcalpha2-3Galbeta1-3GalNAcbeta1-4Galbeta1-4Glcbeta-Cer

Definition

A sialotetraosylceramide consisting of a linear hexasaccharide made up from two sialyl residues, two galactose residues, one N-acetylgalactosamine residue and a glucose residue at the reducing end attached to the ceramide portion via a β-linkage.

References

kegg.glycan:G00126
lipidmaps:LMSP0601BN00
pubmed:1761522
pubmed:2776878
pubmed:3094941
pubmed:3150198
pubmed:8161523
pubmed:9072531
pubmed:9644263

Ontology

ChEBI ( EBI )

Relationships

Phenotype

Phenotype resulting from alpha-Neu5Ac-(2->8)-alpha-Neu5Ac-(2->3)-beta-Gal-(1->3)-beta-GalNAc-(1->4)-beta-Gal-(1->4)-beta-Glc-(1<->1')-Cer

Phenotype where environments contain alpha-Neu5Ac-(2->8)-alpha-Neu5Ac-(2->3)-beta-Gal-(1->3)-beta-GalNAc-(1->4)-beta-Gal-(1->4)-beta-Glc-(1<->1')-Cer

Phenotype modified by environments containing alpha-Neu5Ac-(2->8)-alpha-Neu5Ac-(2->3)-beta-Gal-(1->3)-beta-GalNAc-(1->4)-beta-Gal-(1->4)-beta-Glc-(1<->1')-Cer

Phenotype affecting alpha-Neu5Ac-(2->8)-alpha-Neu5Ac-(2->3)-beta-Gal-(1->3)-beta-GalNAc-(1->4)-beta-Gal-(1->4)-beta-Glc-(1<->1')-Cer

Human Disease Model